澳门老奇人论坛

Meeting Coverage >

GICS

Immunotherapy Not Additive to Standard of Care for Untreated Metastatic CRC

No difference in survival outcomes with add-on nivolumab to chemo, bevacizumab

Potential New First-Line Options for Unresectable Hepatocellular Carcinoma

Tremelimumab-durvalumab improves OS, single-agent durvalumab non-inferior to sorafenib

Pre-Op Immunotherapy Combo Makes Headway in Select Gastric Cancers

Plus, novel bispecific antibody tested as first-line therapy for advanced gastric/GEJ cancer

More Data for Upfront PD-1 Inhibition in Gastric, Esophageal Cancer

Updates from two landmark trials show consistent benefits across subgroups, PD-L1 expression

Preop RT Flunks Test in Borderline Pancreatic Cancer

Chemotherapy alone judged efficacious but not chemoradiation

Drug Hits Target in Advanced Biliary Cancer

Responses in up to a third of patients with FGFR inhibitor infigratinib

Liquid Biopsy Predicts Colon Cancer Relapse Months Before CT

Test for ctDNA outperformed existing biomarker, may help guide therapy

New Target to Attack in Stomach Cancer

PFS, OS improved with fibroblast growth factor receptor inhibitor in non-HER2 disease

Doublet for BRAF-Mutant Colon Cancer Heads to FDA

No need for triplet, encorafenib plus cetuximab matches OS in updated analysis

High Response Rate in HER2+ Esophagogastric Cancer

Summary findings from the Gastrointestinal Cancers Symposium

Death Risk Rises With No Colonoscopy After Stage I CRC

Three-fold increase, but is colonoscopy the driver?

Mixed Results with Immune Tx in Advanced, Refractory Colon Ca

Overall survival gains were modest to none in different stages of CRC

Metastatic Gastric Ca Treatments Show Mixed Results

FTD/TPI effective, but mFOLFOX plus biologic didn't improve survival

'Incredibly Impressive' Activity in Biliary Ca with Combo Tx

Responses in about 40% of patients with BRAF/MEK inhibitor pairing

Combo Therapy Doubles PFS in Unresectable HCC

Chemoembolization plus sorafenib tops embolization alone

Immunotherapy Combo Active in High-Risk CRC

Disease control in 80% with nivolumab-ipilimumab

Extensive Lavage No Help in Gastric Cancer

Survival outcomes not improved with intraperitoneal treatment

Small PFS Bump in Gastric/GEJ Cancer

Clinical vs statistical significance in trial of first-line ramucirumab

QoL Benefits with Palliative Surgery for Gastric Cancer

Solid food intake facilitated, anxiety and pain decreased

Nivolumab Slows Advanced Gastric Cancer

Significant reduction in hazards for survival, PFS in pretreated patients

PET-Guided Therapy Switch for Esophageal Cancer

Improved response with switch from ineffective treatment

Exercise May Extend Survival in Metastatic Colon Cancer

Progression, survival hazards improved with moderate activitiy

Shorter Therapy an Option for High-Risk Anal Cancer

Abbrieviated chemoradiation matches standard with less toxicity

CRC Regimens Give Survival Bump in Second Line

Ramucirumab trial meets primary endpoint; famitinib offers respectable disease control rate.

More Drugs, Better Survival in Metastatic Colon Cancer

Addition of oxaliplatin to FOLFIRI and bevacizumab doubled 5-year survival.

Combo Active in Neuroendocrine Cancers

SAN FRANCISCO -- More than 90% of patients with neuroendocrine tumors had objective responses or stable disease when treated with an off-the-shelf chemotherapy doublet, results of a small study showed.

Surgery Boosts Outcomes in Esophageal Cancer

SAN FRANCISCO -- Surgery after chemoradiotherapy increased overall and disease-free survival compared with chemoradiotherapy alone in advanced esophageal cancer treatment, researchers reported here.

ER Presentation Not the End for Colon Cancer Patients

SAN FRANCISCO -- Curative therapy is still a possibility, even if a colon cancer patient is seen for the first time in the emergency department with acute symptoms, researchers said here.

Gastric Ca Survival Rates Down, Chemo Use Up

SAN FRANCISCO -- A decline in survival rates in stage IV gastric cancer coincides with the increased use of chemotherapy rather than radiation and surgery, researchers found.